AstraZeneca's new heart-drug, Brilique (ticagrelor), has been recommended for treatment of acute coronary syndrome (ACS) by the European Society of Cardiology (ESC).
In the ESC's 2011 guidelines, ticagrelor is recommended for all non-ST elevation ACS patients at moderate-to-high risk of ischaemic events, regardless of initial treatment strategy and including those pre-treated with clopidogrel.
In addition, the guidelines recommend ticagrelor be considered for initiation or resumption following coronary artery bypass graft surgery as soon as it is considered safe.
- The inclusion of ticagrelor in the new NSTE-ACS ESC guidelines is another important step toward improving ACS patient care in the EU, said Professor Lars Wallentin, Professor of Cardiology and Research Director at the Uppsala University, Sweden in a press release.
Ticagrelor is also recommended for treatment of ACS in the Canadian Cardiovascular Society Guidelines.
